Genetic Profile-Guided Therapy for Ovarian Cancer

Overseen By Stephanie Lheureux

Age: 18+

Sex: Female

Trial Phase: Phase 2

Sponsor: University Health Network, Toronto

Must not be taking: Investigational drugs

Disqualifiers: Hypertension, Brain metastases, Autoimmune, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Breakthrough Therapy This drug has been fast-tracked for approval by the FDA given its high promise

Approved in 3 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 4

40 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial examines the effectiveness of using genetic information (biomarkers) from blood and tumor samples to guide treatment for ovarian, fallopian tube, or primary peritoneal cancer. Participants will try different combinations of medications, including Niraparib (a PARP inhibitor), Bevacizumab, and Dostarlimab, to determine which works best. The trial aims to identify the most suitable treatment for individuals whose cancer has returned after using a PARP inhibitor. Eligible participants have experienced a relapse despite previous treatments and have seen recent disease progression. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Do I need to stop my current medications to join the trial?

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot have taken an investigational drug (other than a PARP inhibitor) within 30 days or a PARP inhibitor within 14 days before starting the study treatment.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research shows that using niraparib and bevacizumab together is generally safe for patients. Previous studies found this combination effective in treating advanced ovarian cancer without causing major health problems. The safety of these two medicines together aligns with existing knowledge about them.

When niraparib, bevacizumab, and dostarlimab are used together, studies also show they work well and don't cause new safety issues. Adding dostarlimab doesn't create new health concerns.

The combination of paclitaxel, bevacizumab, and dostarlimab has also been studied. Results suggest these treatments can be effective, and their safety remains stable without major concerns.

Overall, past research supports the safety of these treatment combinations for people with ovarian cancer. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Most treatments for ovarian cancer primarily involve chemotherapy, often with drugs like carboplatin and paclitaxel. However, the treatments in this trial are unique for a few reasons. Niraparib is a PARP inhibitor that targets cancer cells by preventing them from repairing their DNA, leading to cell death. Bevacizumab adds another layer by inhibiting blood vessel growth that tumors need to thrive. Dostarlimab, an immune checkpoint inhibitor, helps the immune system recognize and attack cancer cells. Researchers are excited about these combinations because they offer a multi-pronged attack on the cancer, potentially improving outcomes beyond what traditional chemotherapy alone can achieve.

What evidence suggests that this trial's treatments could be effective for ovarian cancer?

Research has shown that using niraparib and bevacizumab together yields promising results for treating advanced ovarian cancer. One study found that patients lived a median of 61.1 months with this combination, suggesting it can extend life without affecting quality of life. In this trial, participants in Cohort C will receive this combination.

Participants in Cohort A will receive niraparib, bevacizumab, and dostarlimab. Adding dostarlimab to niraparib and bevacizumab has shown positive effects for patients with recurring ovarian cancer. In some cases, patients lived about 20.6 months without disease progression, slightly better than using niraparib alone.

Participants in Cohort B will receive paclitaxel, bevacizumab, and dostarlimab. Studies indicate that combining paclitaxel with bevacizumab and dostarlimab has increased patient responsiveness to treatment and reduced cancer spread. These findings suggest these combinations could be effective options for treating ovarian cancer. ^{2 3 4 6 7}

Who Is on the Research Team?

Stephanie Lheureux

Principal Investigator

Princess Margaret Cancer Centre

Are You a Good Fit for This Trial?

This trial is for patients with ovarian, fallopian tube, or primary peritoneal cancer who have relapsed after PARP inhibitor therapy. They must have a good heart function, measurable disease by RECIST 1.1 criteria, and proper organ function. Women of childbearing potential need to use effective contraception and not breastfeed during the study.

Inclusion Criteria

I agree not to donate blood during and for 3 months after the study.

Patient must agree to not breastfeed during the study or for 30 days after the last dose of study treatment

My cancer has returned after treatment, regardless of how many treatments I've had.

Exclusion Criteria

I have been diagnosed with myelodysplastic syndrome or acute myeloid leukemia.

I have not had major chest or belly surgery in the last 2 weeks or any unhealed surgical cuts.

I don't have lasting side effects from cancer treatment worse than mild.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Biomarker Testing

Blood and tumor tissue samples are collected for biomarker testing to determine the participant's molecular profile

3 weeks

1 visit (in-person)

Initial Treatment

Participants receive bevacizumab and niraparib for 3 cycles, each cycle being 21 days

9 weeks

3 visits (in-person)

Cohort-Specific Treatment

Participants are assigned to a cohort based on genetic testing results and receive a combination of study drugs until disease progression or discontinuation criteria are met

Up to 1 year

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Bevacizumab
• Dostarlimab
• Niraparib
• Paclitaxel

Trial Overview The trial tests if using genetic markers from blood and tumor tissue can guide treatment choices post-PARP inhibitors in cancers like ovarian cancer. It involves drugs Niraparib, Dostarlimab, Bevacizumab, Paclitaxel to see which works best based on these biomarkers.

How Is the Trial Designed?

Group I: Initial/Cohort C Experimental Treatment 2 Interventions

Niraparib by mouth (orally), once a day, every day. Bevacizumab, by vein (intravenously), once every 3 weeks for up to 1 year, then every 6 weeks.

Group II: Cohort B Experimental Treatment 3 Interventions

Paclitaxel, by vein (intravenously), once a week. Bevacizumab, by vein (intravenously), once every 3 weeks for up to 1 year, then every 6 weeks. Dostarlimab, by vein (intravenously), once every 3 weeks for 4 doses, then every 6 weeks afterwards.

Group III: Cohort A Experimental Treatment 3 Interventions

Niraparib by mouth (orally), once a day, every day. Bevacizumab, by vein (intravenously), once every 3 weeks for up to 1 year, then every 6 weeks. Dostarlimab, by vein (intravenously), once every 3 weeks for 4 doses, then every 6 weeks afterwards.

Niraparib is already approved in European Union, United States, Canada for the following indications:

Approved in European Union as Zejula for:

• Maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy
• Maintenance treatment of adults with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy

Approved in United States as Zejula for:

• Maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy
• Treatment of adults with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive status

Approved in Canada as Zejula for:

• Maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy

Who Is Running the Clinical Trial?

University Health Network, Toronto

Lead Sponsor

Trials

1,555

Recruited

526,000+

GlaxoSmithKline

Industry Sponsor

Trials

4,834

Recruited

8,389,000+

Headquarters

London, UK

Known For

Vaccines & Medicines

Top Products

**Advair (salmeterol, fluticasone propionate)**, **Shingrix (shingles vaccine)**, **Augmentin (amoxicillin/clavulanate potassium)**, **Ventolin (salbutamol sulfate)

Dame Emma Walmsley

GlaxoSmithKline

Chief Executive Officer since 2017

MA in Classics and Modern Languages from Oxford University

Dr. Hal Barron

GlaxoSmithKline

Chief Medical Officer since 2018

MD from Harvard Medical School

Published Research Related to This Trial

In a phase 3 trial involving 553 patients with platinum-sensitive, recurrent ovarian cancer, niraparib significantly improved progression-free survival compared to placebo, with median durations of 21.0 months versus 5.5 months for patients with gBRCA mutations, and 12.9 months versus 3.8 months for those with homologous recombination deficiency.

While niraparib was effective, it was associated with moderate bone marrow toxicity, with common grade 3 or 4 adverse events including thrombocytopenia (33.8%), anemia (25.3%), and neutropenia (19.6%), which were managed through dose adjustments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. Mirza, MR., Monk, BJ., Herrstedt, J., et al.[2022]

In a Phase 2 study involving 20 Japanese women with heavily pretreated ovarian cancer, niraparib demonstrated an objective response rate of 35%, indicating that it can effectively reduce tumor size in some patients.

The treatment was generally well-tolerated, with a high disease control rate of 90%, although common side effects included anemia and nausea, and 70% of patients experienced dose reductions or interruptions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer. Okamoto, A., Kondo, E., Nakamura, T., et al.[2021]

Niraparib significantly extends progression-free survival in patients with newly diagnosed advanced ovarian cancer, showing efficacy in both homologous-recombination deficiency positive (HRd) and negative (HRp) populations, based on a phase III trial.

The treatment has a manageable safety profile, with myelosuppression as the main concern, which can be effectively managed through monitoring and individualized dosing based on weight and platelet count.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer. Lee, A.[2022]

In a real-world study of 22 ovarian cancer patients treated with niraparib at a dose of 200 mg/day, the objective response rate was 33.3%, indicating promising efficacy, especially in patients with homologous recombination deficiency (HRD).

The most common adverse events included nausea, thrombocytopenia, and anemia, with severe thrombocytopenia managed through dose adjustments, suggesting that niraparib can be tolerated with appropriate monitoring and management.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China. Ni, J., Cheng, X., Zhao, Q., et al.[2021]

Niraparib significantly improves progression-free survival and other key outcomes in patients with recurrent, platinum-sensitive ovarian cancer, based on the phase III NOVA trial involving a randomized, double-blind, placebo-controlled design.

The treatment has a manageable safety profile, with most serious side effects being blood-related issues, which can be effectively managed through dose adjustments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Niraparib: A Review in Ovarian Cancer. Heo, YA., Duggan, ST.[2019]

In a phase 3 trial involving 733 patients with newly diagnosed advanced ovarian cancer, niraparib significantly improved progression-free survival compared to placebo, with a median of 21.9 months versus 10.4 months for patients with homologous-recombination deficiency.

Niraparib also demonstrated a notable overall survival rate of 84% at 24 months, with manageable side effects, including anemia and thrombocytopenia, but no treatment-related deaths, indicating its safety and efficacy as a treatment option.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. González-Martín, A., Pothuri, B., Vergote, I., et al.[2019]

In a study of 331 patients with recurrent ovarian cancer, niraparib maintenance therapy significantly improved progression-free survival (PFS) in patients with somatic BRCA mutations and those with BRCA wild-type tumors, indicating its efficacy across different genetic backgrounds.

Patients with BRCA wild-type tumors that had other homologous recombination repair (HRR) mutations, as well as those without any HRR mutations, also experienced PFS benefits from niraparib, suggesting its potential as a treatment option regardless of specific mutation status.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects. Mirza, MR., Lindahl, G., Mahner, S., et al.[2023]

Niraparib, a recently approved treatment for recurrent platinum-sensitive ovarian cancer, has demonstrated a high oral bioavailability of 72.7% in humans, indicating effective absorption when taken orally.

The study involved six patients who received a therapeutic dose of 300 mg of niraparib, followed by a small intravenous dose to measure its levels in the bloodstream, confirming its potential as a convenient oral treatment option.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients. van Andel, L., Rosing, H., Zhang, Z., et al.[2019]

In a study of 105 patients with newly diagnosed advanced ovarian cancer, the combination of niraparib and bevacizumab as first-line maintenance therapy resulted in a promising progression-free survival (PFS) rate of 62% at 18 months, with even higher rates in patients with homologous recombination deficiency (76%).

The safety profile of this combination therapy was consistent with the known side effects of the individual drugs, with common treatment-related adverse events including thrombocytopenia, fatigue, and anemia, indicating that the treatment is manageable for patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Hardesty, MM., Krivak, TC., Wright, GS., et al.[2022]

Niraparib is the first PARP inhibitor approved for ovarian cancer treatment in patients without BRCA mutations, showing good tolerability and manageable hematologic side effects, especially with new dose modification guidelines.

Current research is exploring niraparib's effectiveness as a maintenance therapy after platinum-based chemotherapy and in recurrent high-grade serous ovarian cancer, highlighting the need for better biomarkers to identify which patients will benefit most from this treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Niraparib for the treatment of ovarian cancer. Essel, KG., Moore, KN.[2019]

Niraparib is the first FDA- and EMA-approved PARP inhibitor for maintenance therapy in platinum-sensitive ovarian cancer, effective regardless of BRCA status in first-line treatment.

The review highlights niraparib's pharmacological properties and summarizes efficacy and safety data from key trials, indicating its significant role in improving treatment outcomes for ovarian cancer patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting. Maiorano, MFP., Maiorano, BA., Biancofiore, A., et al.[2023]

Citations

1. onclive.com onclive.com/view/frontline-maintenance-with-niraparib-plus-bevacizumab-is-active-in-advanced-ovarian-cancer

Frontline Maintenance With Niraparib Plus Bevacizumab ... Niraparib and bevacizumab combination therapy showed durable overall survival in advanced ovarian cancer without affecting health-related ...

2. sciencedirect.com sciencedirect.com/science/article/pii/S0090825825008819

A phase 2 trial of niraparib plus bevacizumab maintenance ... In the overall population (N = 105), median overall survival was 61.1 months (52.4% maturity). Combination maintenance therapy did not negatively affect health ...

3. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC11672017/

Characteristics and real-world outcomes of patients with ... As over half of all patients present with advanced disease at diagnosis, survival remains low, with a 5-year overall survival rate of only 31.5% ...

4. ascopubs.org ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.5556

Biomarker results from the KGOG3056/NIRVANA-R trial Conclusions: Niraparib rechallenge with bevacizumab showed promising efficacy, particularly in patients with TFIP≥24 months, CR, or normal CA- ...

5. clinicaltrials.gov clinicaltrials.gov/study/NCT06827353

Niraparib Versus Bevacizumab as Maintenance Therapy in ... Objective: To compare the progression-free survival (PFS) of patients with high-grade stage III and IV ovarian carcinoma who received chemotherapy with those ...

6. pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov/40602355/

final analysis and overall survival results from OVARIO In OVARIO, median OS was 61.1 months in the overall population. Safety was consistent with known safety profiles of niraparib and ...

7. clinicaltrials.gov clinicaltrials.gov/study/NCT02354131

Study Details | NCT02354131 | Niraparib Versus ... This is a single-centre, phase 1a, open-label, dose-escalation study to evaluate the safety and tolerability of bevacizumab-niraparib combination.